Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 5

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 5
---
 raw materials. These shortages have cascading effects on patient
care, causing delays in treatment, increasing the risk of medication errors, and requiring the use of less effective alternative treatments.
Hospitals have also experienced increased costs, medication waste, and limited staffing capacity to address and remedy shortages.

We believe that the post-business
combination company will be able to become a new competitive cost producer of drugs made in America. Onboarding the production back to
the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications
through a resilient supply chain made in America.

Investment Criteria

Consistent with our business
strategy, we have identified the following general criteria and guidelines that we believe are important in evaluating prospective targets
for our initial business combination with one or more target companies. We will leverage these criteria and guidelines in evaluating acquisition
opportunities, but we may decide to enter into our initial business combination with a target or targets that do not meet these criteria
and guidelines. We intend to acquire one or more target businesses with the following characteristics:

●Proven
industry leader:  We will seek to acquire a business that is an industry leader that has demonstrated consistent top-line
growth and/or is benefiting from secular tailwinds.

●Defensible and established business models:  We
will seek to acquire a target with sustainable competitive advantages. Though many companies in our industries of interest likely experienced
substantial challenges related to health pandemics, we seek companies with fundamentally sound business models that will recover well.

●Multiple avenues for long-term growth:  We
intend to acquire a company that exhibits long-term growth prospects, with the potential to grow both organically and inorganically through
acquisitions, and demonstrates the ability to drive growth through the enablement or scaling of technology.

3

●Sustainable financial profile:  We
intend to target companies that generate stable free cash-flow and are not reliant on financial leverage to generate returns.

●Compelling value proposition:  We
intend to acquire a fundamentally sound business that is underperforming its potential but presents a compelling value proposition relative
to its peers that may result in an attractive risk-adjusted return for our shareholders.

●Potential for add-on acquisitions:  We
will actively consider target companies that would serve as a strong platform for post-closing add-on acquisitions. Given our extensive
industry networks and collective experience, we believe we will have unique access to a large number